Thread by @MylesMcNulty

We now know that #AVCT's Affimers are being used in at least 5 diagnostics products for #COVID19:

- LFT (with Cytiva)
- BAMS (with Adeptrix)
- ELISA (in-house)
- Microtox BT (with #SKIN)
- Microtox PD (with SKIN)

Working prototypes for all.

And people still doubt Affimers? 1/9

For BAMS and Microtox BT and PD, #AVCT's work is largely complete. It will simply be providing a regular supply of Affimers to Adeptrix and #SKIN, and enjoy steady royalties (which, as many of us are beginning to realise, could be for much longer than initially anticipated).

2/9

This frees up mgmt's time to focus on the proprietary tests, the (all-important!) LFT and the ELISA (which I believe most are under-estimating the earnings potential of).

Whilst some might point out that none of the 5 products have yet been commercialised, I would argue... 3/9

...that the value being built rapidly within the Co will be reflected in the SP much sooner than later. ELISA and BAMS revenues should be commencing imminently, which could provide the required SP catalyst.

Unfortunately, most seem hung up SOLELY on the progress of the LFT. 4/9

For example, #AVCT was DOWN 3%+ this AM, despite having announced another - potentially very lucrative - product. Why? Because it was not news on the LFT.

The LFT will come. Evidently, there have been delays (I would suggest it's a combo of 3 factors outside AVCT's control). 5/9

- CONDOR clinical validation being Gov-run - and thus inevitably poorly organised!

- Lack of patient samples as #COVID19 died down over the summer.

- Delay in tech transfer to BBI (with BBI not having all components ready to go immediately).

To stress: all my own opinion.

6/9

Whatever the case, we've seen so many #COVID19 diagnostics rushed to market in recent months (e.g. people panicking about #AVCT losing mkt share to iAbra, who was then suitably savaged by @FT) that now a few more weeks to commercialisation will not make a difference.

7/9

I believe that #AVCT's CEO wants to get the LFT absolutely perfect, before launch.

It should be obvious to all that the Gov has its hopes pinned on this product: picking up asymptomatic cases is vital to mass, at-home screening. Affimers can provide this.

Developments in... 8/9

..2020 have put #AVCT and its Affimer tech in the frame as a potential super-heavyweight in the global diagnostics industry going forward.

The commercial opp. over the next two years for the Co is quite astonishing.

We'll be holding tightly for that multi-billion valuation. 9/9